TSH and the thyroid on GLP-1 therapy: what the C-cell warning does and does not mean for testing

The thyroid comes up in every GLP-1 conversation because of the boxed warning at the top of every semaglutide and tirzepatide label. It also comes up on lab requests, as a TSH. The two are less connected than most people assume. This page separates them.

What TSH measures

Thyroid-stimulating hormone is made by the pituitary and tells the thyroid how much hormone to produce. When the thyroid underperforms, TSH rises; when it overproduces, TSH falls. It is the single best screening test for thyroid hormone status. MedlinePlus gives a common range of 0.4 to 4.8 µU/mL, notes that values vary during the day (a morning draw is best), that experts disagree on the upper limit, and that some laboratories use a higher upper limit for older people. Ranges differ between labs more than for most tests.

If a TSH is abnormal, the lab or clinician usually adds free T4, and sometimes antibodies, to work out why.

What the boxed warning is about, and why TSH does not test for it

Every one of these labels opens with a warning about thyroid C-cell tumors. In rodents, semaglutide and tirzepatide caused C-cell tumors at clinically relevant exposures; whether they do so in humans is unknown, and the drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2.

C cells make calcitonin. They do not make thyroid hormone, and they do not respond to TSH. A person with MTC usually has a normal TSH. So a TSH before therapy does nothing to address the boxed warning. The test that reflects C cells is calcitonin, and the labels address it directly: routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with these drugs. The labels add that if calcitonin is measured and found elevated the patient should be further evaluated, and that thyroid nodules noted on physical examination or neck imaging should be further evaluated.

What the labels ask instead is a conversation: counsel patients on the potential risk and the symptoms of thyroid tumors (a mass in the neck, difficulty swallowing, shortness of breath, persistent hoarseness), and take a family history.

When a TSH is worth drawing

The labels do not ask for one. There are still three good reasons a prescriber orders it.

You already have a thyroid condition. Anyone on levothyroxine, or with a history of Hashimoto's, Graves' disease or thyroid surgery, has a TSH checked on a schedule anyway. Starting a GLP-1 is a good moment to make sure the last one is recent.

Symptoms overlap. Fatigue, cold intolerance, constipation and hair thinning are symptoms of hypothyroidism. They are also on the adverse reaction lists for these drugs (the Wegovy label lists fatigue, constipation and hair loss among reactions at 5% or more). A TSH sorts out which is which.

Unexplained weight change either way. An underactive thyroid makes weight loss harder; an overactive one causes weight loss on its own. Neither should be missed at the start of a weight program.

Levothyroxine on GLP-1 therapy

Two things change for someone on thyroid replacement.

Body weight falls. Levothyroxine dose requirements are related to body weight, so a dose that was right at 110 kg may be too high at 85 kg. The ATA guideline for hypothyroidism uses TSH to guide dose adjustment; rechecking TSH after substantial weight loss is how an over-replacement is caught.

Gastric emptying slows. The oral semaglutide label reports that levothyroxine exposure was increased 33% (90% CI 1.25 to 1.42) when given with semaglutide tablets in an interaction study, and advises clinical monitoring for oral drugs with a narrow therapeutic index. The injectable labels do not give a number for levothyroxine, but they note that delayed gastric emptying may affect absorption of oral medications. Either way the answer is the same: a TSH some weeks after starting or escalating, timed by your prescriber.

How often

• No thyroid history, no symptoms: no label or guideline sets an interval. Many prescribers include one TSH in the baseline panel; that is a choice.
• On levothyroxine: the recheck interval your prescriber sets after starting therapy and after significant weight loss, then the routine annual check.
• Symptoms: when they appear.

What to discuss with your prescriber

• Any personal or family history of medullary thyroid carcinoma or MEN 2. This is the one thyroid question the labels insist on.
• Any lump in the neck, trouble swallowing or hoarseness, now or later.
• If you take levothyroxine: when TSH will be rechecked and what change would prompt a dose adjustment.

For dosing arithmetic and schedules, see the Tirzepatide Hub and Semaglutide Hub. The boxed warning appears on the brand labels; compounded semaglutide and tirzepatide, including products from FormBlends, are not FDA approved and carry no FDA-reviewed labeling, which is a reason to take the brand labels' warnings as the minimum, not as something that does not apply.